NCCN GUIDELINES AND NCCN COMPENDIUM UPDATED
NCCN Flash Update sent August 18, 2014
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Multiple Myeloma. These NCCN Guidelines® are currently available as Version 1.2015.
- Additional treatment pathway: added “Therapy for previously treated myeloma on or off clinical trial” as an option following progressive disease.
- Under “Preferred Primary Therapy for Non-Transplant Candidates,” added a footnote to lenalidomide/low-dose dexamethasone combination regimen stating “Continuously until progression. Facon T, Dimopoulos MA, Dispenzieri A, et al. Continuous lenalidomide and low-dose dexamethasone demonstrates a significant PFS and OS advantage in transplant ineligible NDMM patients. The FIRST: MM-020/IFM0701 [oral]. Oral presented at: 55th Annual Meeting of the American Society of Hematology (ASH) 2013; December 7-10; New Orleans, LA USA.”
For the complete updated versions of the NCCN Guidelines, NCCN Compendium®, and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org.
To access the NCCN Biomarkers Compendium®, please visit NCCN.org/biomarkers.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patients.
Free NCCN Guidelines apps iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps